PPTA Europe’s Post

New publication 📊   Unraveling the Enigma of Type 2 Low-Inflammation Asthma. AstraZeneca Finland, Medaffcon, and Clinical Experts join forces to delve into the prevalence and stability of this rare, less-explored asthma variant. The study aims to define the disease burden for non-eosinophilic asthma and pinpoint the patient group in need of innovative treatment options. Using data from Auria, TYKS's data lake, our research provides critical insights into this condition.   Auria, the data lake at TYKS, was essentially the only source that offered structured data on not only spirometry tests but also the results of eosinophil and FeNO measurements, according to Dr. Mariann Lassenius, real-world evidence lead at Medaffcon.   ➡ For a comprehensive understanding of the implications for patients, dive into the complete study here: https://lnkd.in/dzEAqbuK #rwe #AsthmaResearch #MedicalInnovations #asthma #realworldevidence

Understanding Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) - A Comprehensive Review https://lnkd.in/dKEFcEp7 🤝 Co-authored with Dr. Hanis Zulkifly, the first Msia PhD graduate under the esteemed Prof. Gregory Lip, this paper delves into the rare but serious condition known as vaccine-induced immune thrombotic thrombocytopenia (VITT). Our comprehensive review, based on analysis of 720 articles, filtered down to 29 significant studies following the PRISMA guidelines, highlights the prevalence, clinical characteristics, and management of VITT. The most common severe manifestation of VITT is cerebral venous sinus thrombosis, with headaches being a primary early symptom. The management of VITT involves the use of intravenous immunoglobulin and non-heparin anticoagulants to address the immune response and thrombosis, respectively. This review not only aims to enhance early recognition and understanding of VITT among healthcare professionals but also to guide the refinement of diagnostic criteria and management strategies. #VITT #COVID19Vaccine #Research #PublicHealth #SunwayUniversity #SMLS

Medialis Ltd Develops First Long-COVID Disease-Specific Quality of Life Instrument: PAC-19QoL In early 2020, as the COVID-19 pandemic reshaped our world, Medialis Ltd recognised the urgent need for a disease-specific quality of life (QoL) instrument for long COVID patients. This, led to the development of the PAC-19QoL. Rapid Development Timeline: We received ethical approval in October 2020 and initiated the development of the PAC-19QoL on November 23, 2020. The PAC-19QoL was completed in just 27 days, finalising it on December 20, 2020. Validation and Publication: The PAC-19QoL was validated on December 29, 2020, and our findings were published in September 2021. For a comprehensive understanding of our work, you can read the full publication here: https://lnkd.in/dPRV3XdS Unique and Reliable Outcome Measure: To the best of our knowledge, the PAC-19QoL is the only validated outcome measure for Long COVID. Our PAC19QoLReg registry (NCT04586413), established to gather data, has confirmed the instrument's reliability in predicting long-term outcomes and assessing patient variation from baseline. Interested in developing disease-specific instruments? Contact us at info@medialis.co.uk to learn how we can assist you. Together, let's continue to innovate and improve patient outcomes! #MedialisLtd #PAC19QoL #LongCOVID #QualityOfLife #DiseaseSpecific #Pandemic #COVID19

📊Our new research indicates that physical activity in COPD is significantly enhanced through pharmacological therapy and behaviour modification interventions. On the contrary, the effect of exercise training on physical activity is not significant or consistent. 📌This is the first meta-analysis providing an estimation of pharmacological treatment effects on steps/day in patients with COPD. 🔍The study also highlights the requirement for reliable, sensitive, and innovative digital mobility outcomes (DMOs). These are necessary to track post-intervention effects by capturing the whole spectrum of mobility. Recommendations for future studies include: ·      drug-specific MCIDs anchored against disease-specific clinical constructs ·      assessing the convergent validity of DMOs. ⬇ https://lnkd.in/dmwpdXPt Mobilise-D Emily Hume Nikolaos Chynkiamis M.Sc., Ph.D. Ashley Polhemus Christopher Buckley @Henrik Watz Thierry Troosters IOANNIS VOGIATZIS

This interesting new publication on better screening, clinical diagnosis, and managing #AutoimmuneDiseases in patients describes a newly created “Systemic Inflammation Index (SII)” that applies data on #biomarkers of #inflammation from patient blood samples of different types of immunological diseases within the autoinflammatory-autoimmune scope. According to the work performed by researchers from the University of Sassari in Italy in collaboration with their Australian colleagues, the Systemic Inflammation Index can differentiate more accurately between patients with immunological diseases and those without (healthy conditions) and between patients with active and inactive conditions. This publication is significant because using SII can lead to more personalized and precise patient detection as well as treatment possibilities. 📖 Read on… https://lnkd.in/eJrszWgT → Publication: Mangoni, A.A., Zinellu, A. The diagnostic role of the systemic inflammation index in patients with immunological diseases: a systematic review and meta-analysis. Clin Exp Med 24, 27 (2024). #medicine #clinicaltrials

A Japonese study confirmed that CT-P13, an intravenous infliximab #biosimilar, demonstrated comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases. This real-world evidence reinforces the confidence in the reliability and effectiveness of CT-P13, offering a valuable alternative for patients in need of treatment. Such studies play a crucial role in expanding access to high-quality healthcare options and advancing the field of biosimilar research. Learn more: https://lnkd.in/eHRUmj6H

🔍 ID-Week Poster Presentation Catch Lisa Husband at IDWeek 2023 this upcoming Saturday, October 14th. 🔬 Lisa will present a poster on "Population pharmacokinetic meta-analysis of BV100 in healthy subjects and renally impaired subjects." 📊 The study dives into a population pharmacokinetic model for BV100, combining the data from our first three clinical studies. This model is especially valuable as it applies to both healthy and renally impaired subjects. 📍 Don't miss Lisa's presentation to deepen your understanding of our transformative work for patients suffering from carbapenem resistant Acinetobacter infections. Date: Saturday 14th October Time: 12:15 - 1:30 PM Location: Halls B + C | PK/PD Studies 📅 For more details and the full conference program, click here https://lnkd.in/dHNhCf6. #IDWeek2023 #InfectiousDiseasesWeek #InfectiousDisease #AMR #BioversysTalks

At the ISLH 2023 meeting In my blog post I neglected to get an important piece of information in on a fine talk on Monitoring Alternative Anticoagulants by Dr. Eric Salazar M.D. for UT Health San Antonio, TX. Dr. Salazar discussed the uses and methods of monitoring direct oral anticoagulants (DOACs). These include Factor Xa inhibitors (anti-FXa) like apixaban, rivaroxaban, and edoxaban, and direct thrombin inhibitors (DTI) like dabigatran, argatroban; and bivalirudin. He talked about real-world situations which may require specialized testing and implementation of laboratory measurement of these anticoagulants. Measuring FXa inhibitors may be warranted in certain situations: With suspected hemorrhaging Patients with a history of bleeding To clear a patient for a surgical procedure When checking for clearance of heparin Beginning a new medication or dose change of medication Elevated D-dimer and PT/INR ESRD/CKD and a decline in renal function Post-reversal of a DOAC Subjects with a BMI> 40 kg/m2 or Weight <60 kg

Early detection of sepsis is crucial in saving lives and improving patient outcomes. Pancreatic Stone Protein (PSP), is a groundbreaking biomarker that offers a new frontier in the early detection of sepsis. Staying informed about the latest advancements in medical science is key to improving patient outcomes and advancing healthcare practices. #SepsisAwareness #HealthcareInnovation #MedicalResearch #PancreaticStoneProtein #EarlyDetection #PatientCare

The CLIA-waived BIOFIRE® SPOTFIRE® Respiratory Panel provides rapid PCR results at the point of care. 🧫 RSV, flu, COVID, and so much more! 🔬 1 PCR Test 🦠 15 Targets ⏰ ~15 Minutes Getting comprehensive results in a clinically actionable timeframe may help inform definitive diagnosis, optimize care, and support antimicrobial stewardship. Discovery the SPOTFIRE System: https://bit.ly/47UiQP0